Literature DB >> 27886905

Cutaneous Manifestation of Drug Allergy and Hypersensitivity.

Anna Zalewska-Janowska1, Radoslaw Spiewak2, Marek L Kowalski3.   

Abstract

Drug hypersensitivity reactions may manifest with either organ-specific or systemic symptoms, but cutaneous eruptions are the most common manifestations. Different medications may cause identical skin symptoms, whereas hypersensitivity to a single drug may manifest with various patterns of symptoms depending on the pathomechanism of hypersensitivity. Drug reactions should be also taken into account in the differential diagnosis of numerous skin rashes. Analysis of morphology of drug-induced lesions, about potential immunologic or nonimmunological mechanisms, is important for the final diagnosis. Thus, here the authors present a morphologic approach to the diagnosis of cutaneous drug-induced eruptions. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cutaneous adverse drug reactions (CADR); Cutaneous manifestations; Drug allergy; Drug hypersensitivity; Photoallergy

Mesh:

Year:  2017        PMID: 27886905     DOI: 10.1016/j.iac.2016.08.006

Source DB:  PubMed          Journal:  Immunol Allergy Clin North Am        ISSN: 0889-8561            Impact factor:   3.479


  4 in total

1.  Treatment of severe drug reactions by hemodialysis.

Authors:  Rokea A El-Azhary; Michael Z Wang; Ashley B Wentworth; LaTonya J Hickson
Journal:  Int J Dermatol       Date:  2017-11-22       Impact factor: 2.736

2.  Pancrelipase-Induced Hypersensitivity Reaction: Case Report and Review of Literature.

Authors:  Jason A Adler; Muhammad W Saif
Journal:  JOP       Date:  2018-09

Review 3.  Sulfonamide Drug Allergy.

Authors:  Joshua M Dorn; Mollie Alpern; Caitlin McNulty; Gerald W Volcheck
Journal:  Curr Allergy Asthma Rep       Date:  2018-06-06       Impact factor: 4.919

Review 4.  Drug-Induced Skin Adverse Reactions: The Role of Pharmacogenomics in Their Prevention.

Authors:  Kalliopi Gerogianni; Aspasia Tsezou; Konstantinos Dimas
Journal:  Mol Diagn Ther       Date:  2018-06       Impact factor: 4.476

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.